Oncology bears a particular potential for translating research findings from the laboratory into clinical applications. Innovative strategies are urgently needed in the areas of diagnosis, patient risk stratification and treatment. The focus of the Division is to develop translational research programmes and clinical research. The tenet of the Division’s plans is that any significant progress toward the cure of cancer can only be based on an improved understanding of its pathogenesis, which, in turn, will lead to the development of improved diagnostics and more rationale therapeutic interventions.
The division is organized into 11 basic research units and 22 clinical research units with a total number of over 130 scientists including clinician-scientists. It comprises the Urological Research Institute (URI). View all the research units here.
Extensive collaborations and joint activities will accelerate the implementation of translational research through access to a large number of patients and samples and combined resource platforms.
The division is joining efforts with the Clinical Departments of Onco-hematology and Oncology to create a virtual cancer center with a network organization, multidisciplinary teams and defined programs for different tumors and takes advantage of the collaborative use of resources, platforms and infrastructures with other Research Divisions and facilities.
- Cancer Genetics;
- Cancer Microenvironment;
- Cancer Immunology and Immunotherapy.
Riva F, Ponzoni M, Supino D, Bertilaccio S, Polentarutti N, Massara M, Pasqualini F, Carriero R, Innocenzi A, Anselmo A, Veliz-Rodriguez T, Simonetti G, Anders H-J, Caligaris-Cappio F, Mantovani A, Muzio M*, Garlanda C*. IL1R8 Deficiency Drives Autoimmunity-Associated Lymphoma Development. Cancer Immunology Research 2019 Jun;7(6):874-885. * Co-corresponding authors
- Alice Dellatomasina, Anna Maria Gasparri, Barbara Colombo, Angelina Sacchi, Mimma Bianco, Tiziana Daniele, Antonio Esposito, Fabio Pastorino, Mirco Ponzoni, Fabrizio Marcucci, Flavio Curnis and Angelo Corti. Spatio-Temporal Regulation of Tumor Angiogenesis by Circulating Chromogranin A Cleavage and Neuropilin-1 Engagement. Cancer Research, February 22, 2019.
- Marco Gaviraghi, Claudia Vivori, Yerma Pareja Sanchez, Francesca Invernizzi, Angela Cattaneo, Benedetta Maria Santoliquido, Michela Frenquelli, Simona Segalla, Angela Bachi, Claudio Doglioni, Vicent Pelechano, Davide Cittaro, Giovanni Tonon, Tumor suppressor PNRC1 blocks rRNA maturation by recruiting the decapping complex to the nucleolus, The EMBO Journal (2018) e99179
- Lavorgna G, Montorsi F, Salonia A, RE: Exercise and Cancer Treatment: Balancing Patient Needs. Lancet Oncol 2018;19:715: Cancer Prevention and Treatment: More than Exercising, Eur Urol., 2018, 74(5)
- Lavorgna G, Montorsi F, Salonia A. Re: Jinjing Chen, Ilaria Guccini, Diletta Di Mitri, et al. Compartmentalized Activities of the Pyruvate Dehydrogenase Complex Sustain Lipogenesis in Prostate Cancer. Nat Genet 2018;50:219-28: Lipid Metabolism in Prostate Cancer: Expanding Patient Therapeutic Opportunities, Eur Urol., 2018, 74(1)
- Lavorgna G, Montorsi F, Salonia A, Re: Ken J. Kron, Alexander Murison, Stanley Zhou, et al. TMPRSS2-ERG Fusion Co-opts Master Transcription Factors and Activates NOTCH Signaling in Primary Prostate Cancer. Nat Genet 2017;49:1336-45, Eur Urol., 2018, 73(4)
Awards and grants
- "Francesca Mancuso" research prize 2018 awarded by Paolo Ghia
Paolo Ghia, deputy director of the division of Experimental oncology and head of B-cell neoplasia Unit, was awarded the prize "Francesca Mancuso 2018" in the field of oncology. The Angela Serra Association for Cancer Research awarded Ghia "for the many important studies conducted to understand the molecular mechanisms responsible for the onset and progression of neoplastic diseases of B lymphocytes".
- A Horizon 2020 project won by Massimo Alfano
Massimo Alfano, senior researcher at Bladder cancer Unit at the Urological Research Institute, won a Horizon 2020 project as coordinators. The project, started on 1 October 2018, is about novel precision technological platforms to promote non-invasive early diagnosis, eradication and prevention of cancer relapse: proof of concept in the bladder carcinoma.
Group leader, Preclinical models of cancer Unit
Paolo Giorgio Arcidiacono
Clinical grouop leader, Biliopancreatic endoscopy and endoscopic ultrasonography Unit
Clinical group leader, Clinical onco-hematology Unit
Group leader, Lymphoid organ development and function Unit
Head, Tumor biology and vascular targeting Unit
Head, Pancreas translational and clinical Unit
Group leader, Biology of multiple myeloma Unit
Andrés José María Ferreri
Head, Lymphoma Unit
Group leader, Tumor microenvironment Unit
Head, B-cell neoplasia Unit and Chronic lymphocytic leukemia Unit
Clinical group leader, Gynecologic oncology Unit
Group leader, Cell signaling Unit
Head, Gastrointestinal surgery Unit
Head, Immuno-biotherapy of melanoma and solid tumors Unit
Pier Alberto Testoni
Head, Gastroenterology and gastrointestinal endoscopy Unit
Head, Functional genomics of cancer Unit
Biliopancreatic endoscopy and endoscopic ultrasonography
Paolo Giorgio Arcidiacono
Biology of Multiple Myeloma
Chronic Lymphocytic Leukemia
Functional genomics of cancer
Gastroenterology and gastrointestinal endoscopy
Pier Alberto Testoni
Immuno-biotherapy of melanoma and solid tumors
Lymphoid organ development
Andrés José Marìa Ferreri
Pancreas translational and clinical Unit
Preclinical models of cancer
Tumor biology and vascular targeting
One postdoctoral position is available under the supervision of Cristina Scielzo on a project founded by AIRC
One postdoctoral position is available at the Division of Experimental Oncology